AXA 安盛中國大陸、香港及澳門行政總裁尹玄慧女士表示:「今年,AXA安盛很榮幸連續第三年贊助『綠色力量環島行』,我們非常高興看到為社區帶來日益增長的正面影響。值得一提的是,本屆活動AXA安盛的參與人數創下歷史新高,反映我們對社區的持續支持。透過此合作,我們成功凝聚社會各界力量,推廣無痕行山、欣賞港島徑自然之美,提升環保意識,同時推動健康生活。我們深信,培養健康的心態與生活模式,對共建更美好、更可持續的未來至關重要。展望未來,我們繼續履行企業社會責任,加強支持香港的環保活動,並與各界同心協力,共建更可持續的未來。」
AXA 安盛致力承擔社會責任,以推動各界應對氣候變化、為社區創造共同價值為重要使命。我們非常榮幸成為首家關注大眾心理健康的保險公司,我們透過提供不同產品、服務,並進行具代表性的研究以提高大眾對心靈健康的關注。我們的整體可持續發展策略建基於氣候相關財務披露工作小組(TCFD)的建議,以氣候政策和提高生物多樣性為重點。我們承諾將環境、社會和管治元素融入我們的業務,務求在投資者、保險供應商、國際模範企業的三大角色上作出貢獻構建可持續未來。
「機構進軍:深入解構全球金融的急速數碼蛻變」(Institutions Are Here: Inside the Rapid Digital Transformation of Global Finance) AlphaTON Capital 策略顧問 Anthony Scaramucci 2 月 11 日(星期三)上午 10:10 – Auros 主舞台
全球思維領袖、AlphaTON 策略顧問 Anthony Scaramucci 將深入剖析區塊鏈及人工智能在機構層面加快採用的趨勢,並探討這兩大技術的融合如何重塑全球金融的格局。
「人工智能時代守護私隱:Telegram 的 Cocoon AI」(Protecting Privacy in the Age of AI: Telegram’s Cocoon AI) AlphaTON Capital 行政總裁 Brittany Kaiser 2 月 11 日(星期三)上午 11:30 – Frontier 舞台
Kaiser 博士將闡述 AlphaTON 作為 Cocoon AI GPU 啟動合作夥伴,如何建構關鍵基礎設施來推動 Telegram 全新 Cocoon AI 計劃中的保密人工智能。此舉將在保障數據所有權及用戶私隱的前提下,為超過 10 億用戶啟用金融、購物及智能支援服務。
獨家非公開拍攝:AlphaTON × Midnight Foundation Podcast 特輯
AlphaTON Capital 行政總裁 Brittany Kaiser 及 Midnight Foundation 主席 Fahmi Syed 「私隱保護,擴展至十億用戶」(Scaling Privacy to a Billion Users)
透過業務營運,AlphaTON Capital 讓公開市場投資者能以機構級別參與 Telegram 生態系統及其十億用戶平台,同時恪守 Nasdaq 上市公司的管治標準及報告透明度。在行政總裁 Brittany Kaiser、執行主席兼投資總監 Enzo Villani 以及業務發展總監 Yury Mitin 的領導下,公司業務版圖橫跨網絡驗證及質押營運、開發以 Telegram 為本的應用程式,以及對 TON 生態系統內的去中心化金融協議、遊戲平台和商業應用進行策略投資。
AlphaTON Capital Corp 在英屬處女群島註冊,於 Nasdaq 上市,股票代號為「ATON」。此外,AlphaTON Capital 透過其原有業務,正推進針對已知檢查點抗性通路的同類首創療法,務求實現持久的治療效果,並提升患者的生活質素。AlphaTON Capital 積極參與藥物開發過程,並提供策略諮詢,以指導新型免疫療法資產及其組合的開發。
「我們相信,真正的奢華絕非遙不可及的仰望,而是可沉浸、可觸摸、可分享的日常體驗。」酒店總經理鄒銳先生(Mr. Jay Zou)表示,「值此寓意團圓與愛意的時節,成都托尼洛•蘭博基尼酒店的亮相意義非凡。我們因極致品味而生,為珍視相聚而設。這裡不僅是一個居停空間,更是一個圍繞『品味、量身、永恆、珍愛』四大支柱構建的體驗閉環。我們願成為佳節中,守護重要關係、昇華歡聚情感的溫暖港灣。」
Mesa, R. A., Kantarjian, H., Tefferi, A., Dueck, A., Levy, R., Vaddi, K., Erickson-Viitanen, S., Thomas, D. A., Cortes, J., Borthakur, G., Pardanani, A. D., Estrov, Z., & Verstovsek, S. (2011). Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer, 117(21), 4869–4877. https://doi.org/10.1002/cncr.26129
Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017.
Mughal, T. I., Vaddi, K., Sarlis, N. J., & Verstovsek, S. (2014). Myelofibrosis‑associated complications: Pathogenesis, clinical manifestations, and effects on outcomes. International Journal of General Medicine, 7, 89–101. https://doi.org/10.2147/IJGM.S51800
Naymagon, L., & Mascarenhas, J. (2017). Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies. HemaSphere, 1(1), e1. https://doi.org/10.1097/HS9.0000000000000001
Naymagon, L., & Mascarenhas, J. (2017). Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies. HemaSphere, 1(1), e1. https://doi.org/10.1097/HS9.0000000000000001
Porter J. B. (2001). Practical management of iron overload. British journal of haematology, 115(2), 239–252. https://doi.org/10.1046/j.1365-2141.2001.03195.x
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.